ArticleAnnals of nuclear medicine2026
Comparison of MRI-, CT- and PET-based anatomical standardization for Centiloid scale calculation in [
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quantitative agreement between AMYclz and CortexID forJapanese journal of radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Centiloid (CL) method is a standardized quantitative approach for amyloid positron emission tomography (PET) that involves the anatomical standardization of PET images. The Global Alzheimer’s Association Interactive Network recommends performing this anatomical standardization using contemporaneously acquired three-dimensional (3D) T1-weighted magnetic resonance imaging (MRI). However, in clinical practice, contemporaneous 3D T1WI is not always available due to outdated imaging or missing sequences. Recently, alternative methods utilizing low-dose computed tomography (CT) scan images from PET/CT scan or PET images themselves for anatomical standardization have been proposed and implemented in commercially available software. This study aimed to compare the CL obtained via MRI-based standardization with CT scan-based and PET-only standardizations. Further, the clinical applicability of these alternative methods was assessed.
methodsWe retrospectively analyzed 68 patients who underwent [18 F]florbetapir PET/CT scan imaging. The CL were calculated using two commercially available software programs—AMYclz® Neuro (PDR Pharma, Tokyo) and BRAINEER® Model A (Splink, Tokyo)—under three conditions: anatomical standardization with MRI, CT scan, and a PET-derived template. The correlations and differences among these methods were evaluated.
results68 patients (age: 70.8 ± 11.2) were included in the analysis. The median CL was 33.87 (3.53–76.57). CT scan-based standardization had lower CL than MRI-based standardization (mean difference: −5.9 ± 4.8). Meanwhile, PET-only standardization had slightly lower CL than MRI-based standardization (-2.1 ± 11.0). The differences in the CL were generally within ± 15. In cases with evidently positive (CL ≥ 50) or clearly negative (CL ≤ 5) findings, the omission of MRI did not affect exceeding the threshold.
conclusionsWhen contemporaneous 3D T1WI is not available, CT scan-based or PET-only anatomical standardization can be a practical alternative for the qualitative assessment of amyloid PET. However, users should recognize that CT scan-based methods have a systematic tendency to underestimate CL values compared with MRI-based methods. Meanwhile, PET-only methods have a tendency to slightly underestimate CL values. The omission of MRI may be acceptable for clear positive or negative cases. However, caution is required for borderline cases, particularly in situations requiring precise quantification such as treatment monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.